scholarly journals P6‐47: Adverse drug reactions and their impact on the treatment of pulmonary tuberculosis in elderly patients

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 246-246
2021 ◽  
pp. 1-4
Author(s):  
Takahiro Kaki ◽  
◽  
Yoshiaki Minakata ◽  
Yoichi Nakanishi ◽  
Seigo Sasaki ◽  
...  

Background: Although there have been some reports about adverse drug reactions (ADRs) in pulmonary tuberculosis treatment, there are few detailed data and the effect of age among elderly patients on ADRs and the period of medication discontinuation due to ADRs is unknown. Purpose: We evaluated the difference in the incidence of ADRs necessitating discontinuation or a change of medication (dADR) among the different age groups and the period of discontinuation in elderly patients undergoing pulmonary tuberculosis treatment. Subjects and Methods: We conducted a retrospective medical record survey of patients who started anti-tuberculosis medication at our hospital from April 1st, 2018 to March 31st, 2020. Results: A total of 120 patients were recruited. There was no significant difference in the incidence of dADR among the different age groups every 10 years in patients ≥50 years of age (p=0.78). The median period of discontinuation was approximately 4 weeks for fever (29.5 days), approximately 3 weeks for rash (18.5 days), approximately 2 weeks for gastrointestinal disorders (16 days), and hepatocellular liver injury (15.5 days), and approximately 1 week for cholestatic liver injury (8 days) and eosinophilia (7 days). Conclusion: The incidence of dADR was not different among the age groups when patients of ≥50 years of age were compared by age. The median times of onset were 1–3 weeks after the start of treatment. The median periods of discontinuation were 1–4 weeks, and the period of discontinuation due to allergic reactions tended to be the longest


2012 ◽  
Vol 12 (4) ◽  
pp. 761-762 ◽  
Author(s):  
Taro Kojima ◽  
Masahiro Akishita ◽  
Yumi Kameyama ◽  
Kiyoshi Yamaguchi ◽  
Hiroshi Yamamoto ◽  
...  

2003 ◽  
Vol 57 (2) ◽  
pp. 121-126 ◽  
Author(s):  
P. A. Routledge ◽  
M. S. O'Mahony ◽  
K. W. Woodhouse

1999 ◽  
Vol 40 (1) ◽  
pp. 41-46 ◽  
Author(s):  
P. CUTRONEO ◽  
S. GRECO ◽  
G. CUCINOTTA ◽  
V. ARCORACI ◽  
A.P. CAPUTI

2021 ◽  
Author(s):  
Apichaya Thontham ◽  
Rapin Polsook

Background: Patients with newly diagnosed pulmonary tuberculosis often suffer from adverse drug reaction symptoms, which leads to the automatic discontinuation of anti-tuberculosis drugs. Thus, understanding symptom experience of adverse drug reactions is necessary.Objective: This study aimed to examine differences in symptoms experienced in four dimensions: presence, frequency, severity, and distress of adverse drug reactions, between male and female patients.Methods: This was a quantitative survey with a cross-sectional design, with data collected between January and April 2020. A total of 394 patients with newly diagnosed pulmonary tuberculosis was selected through a purposive sampling technique. The symptom experiences of adverse drug reactions were measured using a validated instrument. Data were analyzed using mean, standard deviation, and independent t-test.Results: The most commonly reported symptom was itchiness (24.1% in males and 34.9% in females). Vomiting occurred as the most frequent symptom among males (x̅ ± SD = 2.73 ± .88), and fatigue was found to be the most severe and distressing symptom across male patients (x̅ ± SD = 2.50 ± 1.61 and 2.06 ± 1.30, respectively). In contrast, yellowing of the eyes and skin was most frequent and severe among females (x̅ ± SD = 3.17 ± .75 and 3.83 ± 1.47, respectively). In addition, flu-like symptoms were evaluated as the most distressing symptom for female patients (x̅ ± SD = 2.80 ± 1.09). The symptom burdens of the females ranged significantly and reached higher than those of the male patients at a p-value of .05 (t = 3.33).Conclusion: Females taking anti-tuberculosis drugs should be carefully monitored to deal with adverse drug reaction symptoms. This finding would help to decrease the severity of disease and improve their quality of life.Funding: This study received funding from the Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, Bangkok, Thailand (GCUGR1125633058M).


1992 ◽  
Vol 21 (4) ◽  
pp. 294-300 ◽  
Author(s):  
C. M. LINDLEY ◽  
M. P. TULLY ◽  
V. PARAMSOTHY ◽  
R. C. TALLIS

Drugs & Aging ◽  
2009 ◽  
Vol 26 (6) ◽  
pp. 475-482 ◽  
Author(s):  
Pascale Olivier ◽  
Lionel Bertrand ◽  
Marie Tubery ◽  
Dominique Lauque ◽  
Jean-Louis Montastruc ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document